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Introduction
Gp41 of the HIV envelope, especially the MPER, contains highly conserved epitopes recognized by 
neutralizing monoclonal antibodies such as D5, 2F5 and 4E10. The correct presentation of the antigens is 
considered to be key for eliciting neutralizing immune response. The lipid bilayer of liposomes can mimic 
the virus surface and therefore provides the appropriate presentation of this membrane protein. In 
addition, liposomes can integrate the adjuvant monophosphoryl lipid A (MPLA).
The gp41 derivate FPA2 was mutated to increase its solubility and modify its structure for exposure of 
neutralizing epitopes. The protein was expressed in E. coli. The purified protein was solubilized with 
detergent. Liposomes were prepared containing antigen FPA2 and MPLA, a Toll-like receptor 4 agonist, 
using a continuous ethanol crossflow injection technology. Immunogenicity and safety was determined in 
rabbits and macaques. The liposomes formulated in HEC gel were applied i.n. followed by two 
intramuscular boosts in healthy female volunteers in a phase I study of safety and immunogenicity.
This project was funded by the EU 7th framework programme under grant agreement no. 201038, EuroNeut-41.
Results
Liposomes containing FPA2 and MPLA manufactured under GMP conditions were uniform and stable at 2-
8°C. Immunogenicity was demonstrated in rabbits and monkey after mucosal (i.vag., i.n.) prime, followed by 
intramuscular boosts. Immune response was induced systemically and in mucosal surfaces. Preliminary data 
from the clinical phase 1 study in healthy volunteers demonstrated good safety with three nasal 
applications of 200 µg of the formulated protein in HEC gel and of two i.m. boosts.
Conclusion
The liposomal formulation of the gp41 subunit of HIV envelope together with MPLA as adjuvant proved to 
be well tolerated in animals and human. Liposome-formulated FPA2 was able to induce binding antibodies 
measured by ELISA and neutralizing activity in both blood and vaginal secretions in animals. Immunogenicity 
testing in humans is ongoing.
Immunogenicity in Rabbits Immunogenicity in Macaques Clinical Study Design
Liposomal Formulation:
Design & Components
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Flow Chart
Liposomal Formulation: 
Specifications & Stability
Antigen FPA2:
Design & Sequence
Production of Antigen:
Flow Chart
Free Antigen and in
Liposomal Formulation
FP NHR loop CHRpolar tag
MHKVHGSGSGSAVGIGALFLGFLGA
RQLLSGIVQQQNNLLRAIEAQQHLL
QLTVWGIKQLQARILAVERYLKDQQ
DLGIEGCSGKGDCTPEVPWNASDS
NKSLEQIWNNMTWMEWDREINNY
TSLIHSLIEESQNQQEKNEQELLELD
KWASLWNWFNITNWLW
MPER
Hypothesis of design of antigen
:
The fusion peptide (FP) next to the MPER region 
may stabilise it in an immunogenic conformation.
To achieve this, the FP sequence was linked 
directly to the NHR region, removing the polar 
region.
FP-UGR7-MPR-A-2 (FPA2)
Cholesterol    DMPC       DMPG       MPLA         FPA2
          7       :        9        :        1         
Cohort 1, n=6 (2 complete placebo)
intranasal (gel)
20 µg FPA2
16 µg MPLA
intramusular
200 µg FPA2
160 µg MPLA
M1 M2 M3 M5
M0
Cohort 2, n=6 (2 complete placebo)
intranasal (gel)
100 µg FPA2
80 µg MPLA
intramusular
200 µg FPA2
160 µg MPLA
M1 M2 M3 M5
M0
Cohort 3, n=36 (18 i.n. placebo)
intramusular
200 µg FPA2
160 µg MPLA
M1 M2 M3 M5
To date vaccine well tolerated with only infrequent, transient and mild-moderate 
vaccine-related adverse events.
Unblinding and final study report expected by December 2013.
Serum, PBMCs and cervico-vaginal 
secretions collected after each 
immunisation and up to 6 months 
post- final boost for antibody, virus 
neutralising and cellular immune 
responses, and whole blood gene 
expression
intranasal (gel)
200 µg FPA2
160 µg MPLA
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Test Acceptance criteria Release / T 0 T 12M at 2-8°C
milky white suspension
7.4 ± 0.5
? 240 mOsmol/kg
< -10 mV at neutral pH
100 ± 30 nm
? 0.25
sterile
comparable to reference
main band at 18.8 ± 2 kDa
comparable to reference
main band at 18.8 ± 2 kDa
as reported
1.0 ± 0.3 mg/ml
0.8 ± 0.2 mg/ml
9.5 ± 2.5 mg/ml
20 ± 4 mg/ml
2.3 ± 0.6 mg/ml
< 1250 EEU/ml
? 0.5 % (w/v)
< 300 ppm
complies
7.5
298 mOsmol/kg
-14.5 mV
101 nm
0.14
complies
monomer: 15.9 min
dimer: 17.6 min
0.87 mg/ml
0.7 mg/ml
9.2 mg/ml
20 mg/ml
1.8 mg/ml
90 EEU/ml
complies
70 ppm
main band: 19.2 kDa
main band: 18.2 kDa
complies
7.5
298 mOsmol/kg
-16.0 mV
107 nm
0.18
n.d.
monomer: 16.3 min
dimer: 18.1 min
0.75 mg/ml
0.6 mg/ml
8.4 mg/ml
23 mg/ml
1.9 mg/ml
70 EEU/ml
n.d.
n.d.
main band: 18.2 kDa
n.d.
Visual appearance
pH
Osmolality
Membrane surface charge
Mean particle diameter
Polydisperisty index
Sterility
Western blot
SDS-PAGE
Commassie Blue
RP-HPLC, non-reducing
oligomeric state
RP-HPLC, reducing
protein concentration
MPLA content
Cholesterol content
DMPC content
DMPG content
Pyrogenicity (MAT)
Residual ethanol
Residual detergent
SPLE ROUTE
FORMU-
LATION GROUP Ag / Adjuvant Test D-7 D0 D14 D28 D56 D70
D98 We-C
Vag.
We-C
Vest.
IgG - - +++ +++ +++
IgA - - - - +
IgG - - - - -
IgA - - - - -
IgG - + - - - + +++ ++
IgA - - + + + ++ +++ +++
IgG - - - - - - - -
IgA + - - ++ ++ ++ ++ ++
/
/
/
/
D84
/
D35
/
NASAL GEL
Group 13
(R547-552)
Group 4
(R493-498)
Group 4
(R493-498)NASAL GEL
/ (cont.)
/ (cont.)
NS NS
NS
NSNS NS
NS
NS
NS
NS
NS NSCONTROL
CONTROLGroup 13(R547-552)
FP-A/Liposomes/MPLA
FP-A/Liposomes/MPLA
/
/
Prime Prime Prime IM IM
D-7 D35 D56 D70
D0 D14 D28 D56 D84
D0 D28 D98D84
intranasal (gel)
50 µg FPA2
40 µg MPLA
intramuscular
50 µg FPA2
40 µg MPLA
Prime Boost
Immunogenicity data - binding antibodies to FPA2
8 rabbits primed i.n. and boosted i.m. with FPA2 formulated in liposomes with MPLA
8 rabbits immunised as controls with NaCl
Nasal priming alone did not induce antibodies.
IgG mean titre at day 70 was 10 after first i.m. boost.2.6
IgG mean titre at day 98 was 10 after second i.m. boost.4.0
intranasal (gel)
200 µg FPA2
160 µg MPLA
intramuscular
220 µg FPA2
160 µg MPLA
week 0 4 8 12 20 34 43
10x challenge
SHIV162P3, low dose
intravaginally
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Group 1 Serum IgG - FP-A (ng/ml)
FP-A IN (200?g) + IM (200?g)
Weeks (post-immunisation)
IVAG
systemic & local immunigy
binding Abs measured (serum, vaginal)
0 4 8 12 16 20 24 28 32 36 40
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Group 1 Vaginal IgG FP-A (ng/ml)
FPA-IN (200?g) + IM (200?g)
Weeks (post-immunisation)
IVAG
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Group 1 Vaginal IgA FP-A (ng/ml)
FPA-IN (200?g) + IM (200?g)
Weeks (post-immunisation)
IVAG
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Group 1 Serum IgA FP-A (ng/ml)
FPA-IN (200?g) + IM (200?g)
Weeks (post-immunisation)
IVAG
systemic & local immunigy & virology
analysed during challenge
serum
vaginal
IBs solubilisation
washing IBs
by centrifugation
storage of IBs,  -20°C ?
washing IBs 
by centrifugation
(inclusion bodies) 
cell disruption
cell harvest by TFF
(tangential flow filtration)
main fermentation
seed preparation
 BLR(DE3)E. coli
refolding by TFF (WFI)
sterile filtration
AEX chromatography
depth filtration 2
buffer exchange
by TFF
CEX chromatography
depth filtration 1
buffer exchange
by TFF
aqueous phase 1
+ antigen/detergent
aqueous 
phase 2
ethanol solution of
lipids and adjuvant
antigen in 
liposomes
ultra/dia-
filtration
aqueous
phasewaste
final 
bulk product
The crossflow injection technology (Polymun, patent no. EP1337322) is a one-step 
liposome manufacturing process in a closed production system. Liposomes are formed 
when the lipids dissolved in ethanol are injected into the streaming aqueous phase. At 
the same time, the detergent dissolving the membrane antigen is diluted by the ethanol 
and the aqueous phase 2 below the critical micellar concentration, thereby forcing the 
antigen to integrate into the lipid bilayer of the newly formed liposomes. Ethanol and 
detergent are removed by ultra/dia-filtration.
Non-reducting SDS-PAGE of
(A) antigen solubilised with detergent
(B) intermediate liposome suspension before ultra/dia-filtration
(C) final liposomal bulk product containing antigen
(D) ultra/dia-filtrate
The antigen is mainly presented as monomer, partly as dimer.
15 kD
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20 kD
25 kD
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